London, UK and Boston, MA - Image Analysis Group (IAG) announced today that they have partnered with a new CRO spun out by BMC/BUSM Radiology to provide life sciences, biotech, medical device and pharmaceutical clients with expert clinical research services in imaging.
This partnership will offer IAG’s proprietary cloud-based platform Dynamika for clinical trial data management, patented advanced image analysis algorithms for imaging data analysis, and renowned scientific and analytical expertise of the radiologists to conduct global clinical trials.
The partnership will allow for BMC/BUSM Radiology to market IAG’s industry leading cloud based software platform for clinical trial data management and image analysis DYNAMIKA while IAG’s’ clients will benefit from BMC/BUSM radiology and clinical services expertise in oncology, immune-oncology, neuro-oncology, neurology and inflammation. The new partners will work in tandem to provide trial and endpoint design, trial management, site selection and management, project management, technical expert and radiology services globally.
“We believe that the combination of the technology platform, algorithms and services and with BMC Radiology’s medical depth creates a clinical trial imaging management team unrivalled in the industry”, commended Dr. Olga Kubassova, CEO of Image Analysis Group.
“We are pleased to gain a partner with such complementary skills and look forward to working together,” added the president of Boston Radiology Associates, Dr. Jorge Soto.
About Image Analysis Group
Image Analysis Group is an expert clinical research organization, delivering systems, scientific expertise and full service to support efficient design and execution of clinical trials, where imaging provides critical evidence of the novel compound safety and efficacy.
About BMC/BUSM Radiology
Boston Medical Center Radiology is a group of academic radiologists with research expertise and extensive clinical trials experience in all specialties including oncology, neuro-oncology, trauma etc. Members of the department have recognized proficiency in clinical trials design, execution and management.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.